GSK and MMV announce FDA Breakthrough Therapy designation for tafenoquine for Plasmodium vivax malaria

GlaxoSmithKline (GSK) and Medicines for Malaria Venture (MMV) announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for tafenoquine.
Source: GSK news - Category: Pharmaceuticals Source Type: news